BACKGROUND AND OBJECTIVE Management of oral lichen planus (OLP) is challenging and therapeutic options are limited. The use of topical tacrolimus has shown promising results. We reviewed our daily life experience with topical tacrolimus in OLP patients. METHODS This retrospective unicentre study included all 21 patients with OLP, which were evaluated over a 53-month period and treated with topical tacrolimus. Patients were initially given a topical preparation of 0.1% tacrolimus twice daily. The response to treatment was assessed using a 4-point scale at month 2 and 6: complete response of affected area (CR), major remission (>50%, MR), partial remission (25-50%, PR) and either no response (<25%) or worsening. The pain score was al...
Abstract Background: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown...
BACKGROUND: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology ...
Background: Oral lichen planus (OLP) is a chronic inflammatory disease, affecting nearly 1-2% of the...
BACKGROUND AND OBJECTIVE Topical tacrolimus has been shown to be beneficial in the treatment of o...
BACKGROUND: Erosive oral lichen planus (LP) is a painful chronic inflammatory condition that is freq...
AimOral lichen planus (OLP) is a common, chronic inflammatory disease of the oral mucosa. Although s...
Background and objectives: Oral lichen planus (OLP) is a relatively common, chronic inflammatory con...
Introduction: Corticosteroids were the treatment of option for symptomatic oral lichen planus. How...
Abstract Objective: To carry out a double-blind randomized controlled trial (RCT) to compare the eff...
OBJECTIVE: Our purpose was to investigate the efficacy and safety of 0.1% topical tacrolimus in eros...
<p><strong>Background and aims.</strong> Oral lichen planus (OLP) is a common chro...
Oral Lichen Planus (OLP) is a chronic inflammatory condition that affects mucous membranes into the ...
This study was carried out to assess and compare the efficacy of tacrolimus and clobetasol in the tr...
AbstractObjectivesThe purpose of this study was to investigate the efficacy and safety of 0.1% tacro...
Oral lichen planus (OLP) is a common chronic inflammatory disease associated with cell-mediated immu...
Abstract Background: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown...
BACKGROUND: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology ...
Background: Oral lichen planus (OLP) is a chronic inflammatory disease, affecting nearly 1-2% of the...
BACKGROUND AND OBJECTIVE Topical tacrolimus has been shown to be beneficial in the treatment of o...
BACKGROUND: Erosive oral lichen planus (LP) is a painful chronic inflammatory condition that is freq...
AimOral lichen planus (OLP) is a common, chronic inflammatory disease of the oral mucosa. Although s...
Background and objectives: Oral lichen planus (OLP) is a relatively common, chronic inflammatory con...
Introduction: Corticosteroids were the treatment of option for symptomatic oral lichen planus. How...
Abstract Objective: To carry out a double-blind randomized controlled trial (RCT) to compare the eff...
OBJECTIVE: Our purpose was to investigate the efficacy and safety of 0.1% topical tacrolimus in eros...
<p><strong>Background and aims.</strong> Oral lichen planus (OLP) is a common chro...
Oral Lichen Planus (OLP) is a chronic inflammatory condition that affects mucous membranes into the ...
This study was carried out to assess and compare the efficacy of tacrolimus and clobetasol in the tr...
AbstractObjectivesThe purpose of this study was to investigate the efficacy and safety of 0.1% tacro...
Oral lichen planus (OLP) is a common chronic inflammatory disease associated with cell-mediated immu...
Abstract Background: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown...
BACKGROUND: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology ...
Background: Oral lichen planus (OLP) is a chronic inflammatory disease, affecting nearly 1-2% of the...